Theodore M Brasky1, Kirsten B Moysich2, David E Cohn3, Emily White4. 1. The Ohio State University College of Medicine, Department of Internal Medicine, Division of Cancer Prevention & Control, Columbus, OH, USA; Fred Hutchinson Cancer Research Center, Cancer Prevention Program, Seattle, WA, USA. Electronic address: Theodore.Brasky@osumc.edu. 2. Roswell Park Cancer Institute, Division of Cancer Prevention and Population Sciences, Buffalo, NY, USA. 3. The Ohio State University College of Medicine, Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Columbus, OH, USA. 4. Fred Hutchinson Cancer Research Center, Cancer Prevention Program, Seattle, WA, USA.
Abstract
OBJECTIVE: Chronic inflammation may be an important factor in the initiation and promotion of endometrial cancer. Use of non-steroidal anti-inflammatory drugs (NSAIDs), however, has been inconsistently associated with endometrial cancer risk. METHODS: 22,268 female residents of western Washington State, ages 50-76, completed a baseline questionnaire in 2000-2002 and reported on their use of individual NSAIDs over the past 10years. Use was categorized as none, low (<4days/week or <4years), and high (≥4days/week and ≥4years). Over 9years of follow-up, 262 incident invasive endometrial cancers were identified. Multivariable proportional hazards models were used to estimate hazard ratios (HR) and 95% confidence intervals (CI). RESULTS: Relative to non-use, high use of aspirin was inversely associated with endometrial cancer risk (HR 0.64, 95% CI: 0.41-1.01; P trend=0.03). Findings were stronger for regular-strength than low-dose aspirin. High use of non-aspirin NSAIDs (HR 1.15, 95% CI: 0.68-1.95), including ibuprofen (HR 1.29, 95% CI: 0.73-2.28), and naproxen (HR 1.08, 95% CI: 0.39-2.95) was not associated with risk. In subgroup analyses, findings for aspirin were strongest for cancers of endometrioid histology and were restricted to non-smokers. CONCLUSIONS: This study provides additional evidence that use of aspirin, but not non-aspirin NSAIDs, may reduce the risk of endometrial cancer, especially in estrogen-mediated cases; however additional prospective studies with high-quality measurement of NSAID use are needed. Aspirin should continue to be examined as a potential agent for cancer chemoprevention.
OBJECTIVE:Chronic inflammation may be an important factor in the initiation and promotion of endometrial cancer. Use of non-steroidal anti-inflammatory drugs (NSAIDs), however, has been inconsistently associated with endometrial cancer risk. METHODS: 22,268 female residents of western Washington State, ages 50-76, completed a baseline questionnaire in 2000-2002 and reported on their use of individual NSAIDs over the past 10years. Use was categorized as none, low (<4days/week or <4years), and high (≥4days/week and ≥4years). Over 9years of follow-up, 262 incident invasive endometrial cancers were identified. Multivariable proportional hazards models were used to estimate hazard ratios (HR) and 95% confidence intervals (CI). RESULTS: Relative to non-use, high use of aspirin was inversely associated with endometrial cancer risk (HR 0.64, 95% CI: 0.41-1.01; P trend=0.03). Findings were stronger for regular-strength than low-dose aspirin. High use of non-aspirin NSAIDs (HR 1.15, 95% CI: 0.68-1.95), including ibuprofen (HR 1.29, 95% CI: 0.73-2.28), and naproxen (HR 1.08, 95% CI: 0.39-2.95) was not associated with risk. In subgroup analyses, findings for aspirin were strongest for cancers of endometrioid histology and were restricted to non-smokers. CONCLUSIONS: This study provides additional evidence that use of aspirin, but not non-aspirin NSAIDs, may reduce the risk of endometrial cancer, especially in estrogen-mediated cases; however additional prospective studies with high-quality measurement of NSAID use are needed. Aspirin should continue to be examined as a potential agent for cancer chemoprevention.
Authors: R W Field; B J Smith; C E Platz; R A Robinson; J S Neuberger; C P Brus; C F Lynch Journal: J Natl Cancer Inst Date: 2004-07-21 Impact factor: 13.506
Authors: Annette S Neill; Christina M Nagle; Melinda M Protani; Andreas Obermair; Amanda B Spurdle; Penelope M Webb Journal: Int J Cancer Date: 2012-07-27 Impact factor: 7.396
Authors: Nancy R Cook; I-Min Lee; J Michael Gaziano; David Gordon; Paul M Ridker; JoAnn E Manson; Charles H Hennekens; Julie E Buring Journal: JAMA Date: 2005-07-06 Impact factor: 56.272
Authors: Jeffrey M Fowler; Nilsa Ramirez; David E Cohn; Nicole Kelbick; James Pavelka; Inbar Ben-Shachar; Carl Morrison Journal: Am J Obstet Gynecol Date: 2005-04 Impact factor: 8.661
Authors: Emily White; Ruth E Patterson; Alan R Kristal; Mark Thornquist; Irena King; Ann L Shattuck; Ilonka Evans; Jessie Satia-Abouta; Alyson J Littman; John D Potter Journal: Am J Epidemiol Date: 2004-01-01 Impact factor: 4.897
Authors: Hannah P Yang; Alan Meeker; Richard Guido; Marc J Gunter; Gloria S Huang; Patricia Luhn; Lori d'Ambrosio; Nicolas Wentzensen; Mark E Sherman Journal: Cancer Causes Control Date: 2015-09-16 Impact factor: 2.506
Authors: P M Webb; R Na; E Weiderpass; H O Adami; K E Anderson; K A Bertrand; E Botteri; T M Brasky; L A Brinton; C Chen; J A Doherty; L Lu; S E McCann; K B Moysich; S Olson; S Petruzella; J R Palmer; A E Prizment; C Schairer; V W Setiawan; A B Spurdle; B Trabert; N Wentzensen; L Wilkens; H P Yang; H Yu; H A Risch; S J Jordan Journal: Ann Oncol Date: 2019-02-01 Impact factor: 32.976
Authors: Theodore M Brasky; Todd R Sponholtz; Julie R Palmer; Lynn Rosenberg; Edward A Ruiz-Narváez; Lauren A Wise Journal: Am J Epidemiol Date: 2016-01-10 Impact factor: 4.897
Authors: Theodore M Brasky; Rebecca J Rodabough; Jingmin Liu; Michelle L Kurta; Lauren A Wise; Tonya S Orchard; David E Cohn; Martha A Belury; Emily White; JoAnn E Manson; Marian L Neuhouser Journal: Am J Clin Nutr Date: 2015-03-04 Impact factor: 7.045
Authors: Theodore M Brasky; Ashley S Felix; David E Cohn; D Scott McMeekin; David G Mutch; William T Creasman; Premal H Thaker; Joan L Walker; Richard G Moore; Shashikant B Lele; Saketh R Guntupalli; Levi S Downs; Christa I Nagel; John F Boggess; Michael L Pearl; Olga B Ioffe; Kay J Park; Shamshad Ali; Louise A Brinton Journal: J Natl Cancer Inst Date: 2017-03-01 Impact factor: 13.506
Authors: Lauren M Hurwitz; Aladdin H Shadyab; Fred K Tabung; Garnet L Anderson; Nazmus Saquib; Robert B Wallace; Robert A Wild; Ruth M Pfeiffer; Xia Xu; Britton Trabert Journal: Cancer Prev Res (Phila) Date: 2022-03-01
Authors: Elizabeth D Kantor; Christina C Newton; Edward L Giovannucci; Marjorie L McCullough; Peter T Campbell; Eric J Jacobs Journal: Cancer Causes Control Date: 2018-02-06 Impact factor: 2.506